Notizia - Recent Pharma, Healthcare and Biotech Happenings
DelveInsight
by
6d ago
FDA Grants Approval to Caris Life Sciences for MI Cancer Seek; Johnson & Johnson MedTech Secures FDA IDE Approval for OTTAVA; Organogenesis Shares Positive Interim Data from Second Phase 3 Study of ReNu; LivaNova’s OSPREY Trial Achieves Key Safety and Efficacy Milestones; Hyperfine Launches Advanced Portable MR Brain Imaging Swoop® System Across Europe; Nihon Kohden Strengthens Neurological Solutions Through Ad-Tech Medical Instrument Corporation Acquisition ..read more
Visit website
Recent Article
DelveInsight
by
3M ago
Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market ..read more
Visit website
Articles
DelveInsight
by
3M ago
CELMoDs – A Worthy Successor to REVLIMID ..read more
Visit website
CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for...
DelveInsight
by
3M ago
CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The ..read more
Visit website
Mobile Health Apps for Obesity Treatment: A Modern Solution to a Growing Problem
DelveInsight
by
3M ago
Obesity is the second leading cause of preventable death, associated with a range of inflammatory ..read more
Visit website
Late-Stage Thyroid Eye Disease Treatments: 4 Prominent Therapies to Consider
DelveInsight
by
3M ago
With an estimated 1 million patients affected in the US, thyroid eye disease is a ..read more
Visit website
Top 7 Breakthrough Drugs for Ulcerative Colitis Treatment
DelveInsight
by
4M ago
Ulcerative colitis is a type of inflammatory bowel disease of unknown origin that targets the ..read more
Visit website
Eli Lilly strengthening its Gastroenterology portfolio post Acquisition of Mo...
DelveInsight
by
4M ago
In a strategic move aimed at bolstering its portfolio in inflammatory bowel disease (IBD) treatments ..read more
Visit website
FcRn Inhibitors Being The Fastest Growing Class, Plans To Get Explored In 20+...
DelveInsight
by
4M ago
Vyvgart enjoying strong commercial uptake whereas RYSTIGGO is preferred for MuSK+ Myasthenia gravis. What do ..read more
Visit website
Immutep’ First-Line Treatment Positive Outcomes; Pfizer’s Once-Daily Oral GLP...
DelveInsight
by
4M ago
Immutep Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell ..read more
Visit website

Follow DelveInsight on FeedSpot

Continue with Google
Continue with Apple
OR